-- Grande Portage Resources (GPG.V) 週三表示，該公司已啟動一項「正式、全面的」地球化學表徵計劃，以推進位於阿拉斯加東南部的 New Amalga 金礦項目的許可審批。樣品已於 4 月 24 日寄出。 地球化學特性分析是金屬礦開採專案的標準環境研究，該測試旨在確定專案將開採的不同類型岩石是否具有長期反應性（產生酸並導致金屬釋放）。該公司指出，先前在 2020-2021 年對少量 New Amalga 圍岩樣本進行的有限測試結果令人滿意，所有測試樣本均顯示出顯著的淨酸中和率。 該公司表示，目前的計劃將測試數量更多的樣品，這些樣品代表了根據初步經濟評估 (PEA) 礦山計劃（生效日期為 2026 年 2 月 11 日）計劃開採區域內的不同岩石類型。 根據初步經濟評估（PEA）的礦山計劃，所有礦山開發過程中產生的岩石和礦石分選廢料都將返還地下，主要以膠結充填物（CRF）的形式回填，礦山關閉後不會有任何廢石留在地表堆場。該公司補充道，測試計畫還將首次利用新阿瑪爾加（New Amalga）材料製備膠結充填物。 「地球化學計畫的啟動是我們環境研究進展中的一個重要里程碑，」總裁兼首席執行官伊恩·克拉森（Ian Klassen）表示，「該計畫的結果將成為聯邦《國家環境政策法案》（NEPA）環境審查流程以及阿拉斯加州採礦許可證申請的關鍵依據。充填物測試還將提供重要數據，為未來的工程和成本研究提供資訊。 GPG的股價昨日下跌0.03美元，至0.365美元。
Related Articles
Research
Research Alert: CFRA Downgrades Rating To Sell From Hold On Shares Of Essex Property Trust, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target by $15 to $250 using a narrower equity risk premium and a forward P/FFO of 15.5x, which is in line with the multifamily residential REIT average. We keep our 2026 FFO estimate at $16.15 and lower 2027's by $0.05 to $16.45 on respective revenue projections of $1.94B and $1.98B. Rental revenue is not yet rebounding to historical growth levels. Across the industry, we are seeing inflation in key operating expenses exceeding revenue growth, and this leads to modest gains in cash NOI growth Y/Y. We expect these market conditions to continue as pricing power for ESS and its peers seems to have eased. In particular, ESS has a West Coast portfolio profile that is exposed to significant job layoffs in the technology sector. In our opinion, we have not yet seen the tail risk of major announcements just released in recent weeks. ESS has the challenge of complying with strict housing guidelines in California, leading to the trust historically underperforming peers in other parts of the country.
$ESS
Research
Research Alert: CFRA Keeps Buy Rating On Shares Of Biogen Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $236, 13.8x our new 2027 EPS view, a discount to BIIB's five-year historical forward P/E average of 14.1x. We lower our 2026 EPS view to $15.24 from $16.14 to adjust for the impact from acquired IPR&D. We keep our 2027 EPS view at $17.16. BIIB reported a strong start to 2026, with sales of $2.5B and adjusted EPS of $3.57. We see a successful stabilization of the business after years of decline, due to a 12% Y/Y increase in the growth products portfolio. In our view, during the analyst call, management presented a clear strategic vision centered on the pending $5.6B acquisition of Apellis, expected to close in Q2, which can transform BIIB into a growth company by adding two commercial assets, Syfovre and Empaveli. We think the Apellis deal could bridge a revenue gap until 2028, when the company's late-stage pipeline matures. Via this acquisition, BIIB also gains nephrology expertise and an established infrastructure, which could set its key asset Felzartamab launch for success.
$BIIB
Australia
Starbucks to Sustain Sales Momentum; to Focus on Margins in H2, UBS Says
Starbucks (SBUX) is expected to maintain solid sales momentum on its turnaround strategy, though investor focus is shifting toward margin recovery in H2, UBS said in a note on Wednesday.The brokerage said strong transaction-driven comparable sales growth in Q2 reflected improvements in operations, menu innovation and updated loyalty program.Looking ahead, UBS said continued execution on initiatives such as afternoon beverage platforms, loyalty enhancements, store closures and operational improvements should support sales into H2.UBS also expects margin expansion later in the year, supported by sales leverage, cost savings and easing pressures from tariffs and coffee costs.UBS raised the price target on the stock to $105 from $100 but maintained a neutral rating.Price: $106.10, Change: $+8.82, Percent Change: +9.06%
$SBUX